Chakma Justin
Known title: Chief Business OfficerCIK: 0001951238
Associated companies
Transaction History
| SPRY | ▲ Buy | Option Exercise | 30,000 | $25K | 11/12/2025 | View on chart |
| SPRY | ▼ Sell | Open Market | 30,000 | $267K | 11/12/2025 | View on chart |
| SPRY | ▼ Sell | Open Market | 136,380 | $1.2M | 11/12/2025 | View on chart |
| SPRY | ▼ Sell | Open Market | 27,272 | $329K | 12/13/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 27,272 | $39K | 12/13/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 117,333 | $1.4M | 12/12/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 117,333 | $99K | 12/12/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 50,000 | $42K | 12/10/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 50,000 | $658K | 12/10/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 50,000 | $42K | 12/6/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 50,000 | $712K | 12/6/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 49,640 | $42K | 12/5/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 49,640 | $702K | 12/5/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 45,000 | $38K | 12/4/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 45,000 | $628K | 12/4/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 3,260 | $3K | 12/3/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 41,740 | $35K | 12/3/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 45,000 | $593K | 12/3/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 45,000 | $38K | 12/2/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 45,000 | $615K | 12/2/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 25,000 | $360K | 11/27/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 42,186 | $593K | 11/26/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 32,814 | $459K | 11/25/2024 | View on chart |
| SPRY | ▲ Buy | Grant | 236,380 | — | 11/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Aquestive news highlights biotech valuation dynamics
Recent market discussion focused on Aquestive Therapeutics and the pricing of anaphylaxis drug success. While this news does not directly involve ARS Pharmaceuticals, it reflects broader sector sentiment regarding biotech valuations. ARS Pharmaceuticals is currently trading with an RSI of 37.5, indicating mild oversold conditions relative to its recent range.
Aquestive news highlights biotech valuation dynamics. Recent market discussion focused on Aquestive Therapeutics and the pricing of anaphylaxis drug success. While this news does not directly involve ARS Pharmaceuticals, it reflects broader sector sentiment regarding biotech valuations. ARS Pharmaceuticals is currently trading with an RSI of 37.5, indicating mild oversold conditions relative to its recent range.